BH3:FRA
PTC Therapeutics, Inc.
€ 55.00
arrow_downward
-0.61%(-0.34) Siku 1
9 Okt, 22:00:00 GMT +2 · EUR
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya BH3...
Fungua
€ 55.00
Juu
€ 55.00
Chini
€ 55.00
Mtaji wa soko
5.40B
Wastani wa kiasi cha mauzo
0.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
€ 77.02
Chini kwa wiki 52
€ 52.50
Idadi ya wafanyakazi
991
Fungua
€ 55.00
Juu
€ 55.00
Chini
€ 55.00
Mtaji wa soko
5.40B
Wastani wa kiasi cha mauzo
0.00
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
€ 77.02
Chini kwa wiki 52
€ 52.50
Idadi ya wafanyakazi
991
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
MarketBeat
·
saa 2 zilizopita
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Has Consensus Target Price of $98.25 According to Brokerages
Investing.com Canada
·
saa 10 zilizopita
Form 4 PTC Therapeutics Inc For: 9 October By Investing.com
Stock Titan
·
saa 12 zilizopita
Officer Mark Elliott Boulding proposes selling 192 shares of PTC Therapeutics (Nasdaq: PTCT).
Yahoo Finance
·
siku 2 zilizopita
PTC Therapeutics, Inc. (PTCT) Stock Forecasts
Wasifu
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
Kuhusu PTC Therapeutics, Inc.
Afisa Mkuu Mtendaji (CEO)Matthew B. Klein
Wafanyakazi991
Lilianzishwa1 Jan 1998
Makao makuuWarren, New Jersey, Marekani
Sekta-
Tovutiptcbio.com